Andrew J Bishop1, Brad Greenfield2, Anita Mahajan1, Arnold C Paulino3, M Fatih Okcu4, Pamela K Allen1, Murali Chintagumpala4, Lisa S Kahalley5, Mary F McAleer1, Susan L McGovern1, William E Whitehead6, David R Grosshans7. 1. Department of Radiation Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas. 2. Department of Radiation Oncology, Baylor College of Medicine, Houston, Texas. 3. Department of Radiation Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas; Department of Radiation Oncology, Baylor College of Medicine, Houston, Texas. 4. Department of Pediatrics, Texas Children's Cancer and Hematology Center, Baylor College of Medicine, Houston, Texas. 5. Section of Psychology, Texas Children's Cancer and Hematology Center, Baylor College of Medicine, Houston, Texas. 6. Department of Neurosurgery, Texas Children's Cancer and Hematology Center, Baylor College of Medicine, Houston, Texas. 7. Department of Radiation Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas. Electronic address: dgrossha@mdanderson.org.
Abstract
PURPOSE: We compared proton beam therapy (PBT) with intensity modulated radiation therapy (IMRT) for pediatric craniopharyngioma in terms of disease control, cyst dynamics, and toxicity. METHODS AND MATERIALS: We reviewed records from 52 children treated with PBT (n=21) or IMRT (n=31) at 2 institutions from 1996-2012. Endpoints were overall survival (OS), disease control, cyst dynamics, and toxicity. RESULTS: At 59.6 months' median follow-up (PBT 33 mo vs IMRT 106 mo; P<.001), the 3-year outcomes were 96% for OS, 95% for nodular failure-free survival and 76% for cystic failure-free survival. Neither OS nor disease control differed between treatment groups (OS P=.742; nodular failure-free survival P=.546; cystic failure-free survival P=.994). During therapy, 40% of patients had cyst growth (20% requiring intervention); immediately after therapy, 17 patients (33%) had cyst growth (transient in 14), more commonly in the IMRT group (42% vs 19% PBT; P=.082); and 27% experienced late cyst growth (32% IMRT, 19% PBT; P=.353), with intervention required in 40%. Toxicity did not differ between groups. On multivariate analysis, cyst growth was related to visual and hypothalamic toxicity (P=.009 and .04, respectively). Patients given radiation as salvage therapy (for recurrence) rather than adjuvant therapy had higher rates of visual and endocrine (P=.017 and .024, respectively) dysfunction. CONCLUSIONS: Survival and disease-control outcomes were equivalent for PBT and IMRT. Cyst growth is common, unpredictable, and should be followed during and after therapy, because it contributes to late toxicity. Delaying radiation therapy until recurrence may result in worse visual and endocrine function.
PURPOSE: We compared proton beam therapy (PBT) with intensity modulated radiation therapy (IMRT) for pediatric craniopharyngioma in terms of disease control, cyst dynamics, and toxicity. METHODS AND MATERIALS: We reviewed records from 52 children treated with PBT (n=21) or IMRT (n=31) at 2 institutions from 1996-2012. Endpoints were overall survival (OS), disease control, cyst dynamics, and toxicity. RESULTS: At 59.6 months' median follow-up (PBT 33 mo vs IMRT 106 mo; P<.001), the 3-year outcomes were 96% for OS, 95% for nodular failure-free survival and 76% for cystic failure-free survival. Neither OS nor disease control differed between treatment groups (OS P=.742; nodular failure-free survival P=.546; cystic failure-free survival P=.994). During therapy, 40% of patients had cyst growth (20% requiring intervention); immediately after therapy, 17 patients (33%) had cyst growth (transient in 14), more commonly in the IMRT group (42% vs 19% PBT; P=.082); and 27% experienced late cyst growth (32% IMRT, 19% PBT; P=.353), with intervention required in 40%. Toxicity did not differ between groups. On multivariate analysis, cyst growth was related to visual and hypothalamic toxicity (P=.009 and .04, respectively). Patients given radiation as salvage therapy (for recurrence) rather than adjuvant therapy had higher rates of visual and endocrine (P=.017 and .024, respectively) dysfunction. CONCLUSIONS: Survival and disease-control outcomes were equivalent for PBT and IMRT. Cyst growth is common, unpredictable, and should be followed during and after therapy, because it contributes to late toxicity. Delaying radiation therapy until recurrence may result in worse visual and endocrine function.
Authors: Quoc T Luu; Lilia N Loredo; John O Archambeau; Les T Yonemoto; James M Slater; Jerry D Slater Journal: Cancer J Date: 2006 Mar-Apr Impact factor: 3.360
Authors: Thomas E Merchant; Erin N Kiehna; Larry E Kun; Raymond K Mulhern; Chenghong Li; Xiaoping Xiong; Frederick A Boop; Robert A Sanford Journal: J Neurosurg Date: 2006-02 Impact factor: 5.115
Authors: David B Mansur; Joshua B Rubin; Elizabeth A Kidd; Allison A King; Abby S Hollander; Matthew D Smyth; David D Limbrick; T S Park; Jeffrey R Leonard Journal: Int J Radiat Oncol Biol Phys Date: 2010-04-24 Impact factor: 7.038
Authors: Karen M Winkfield; Claudia Linsenmeier; Torunn I Yock; P Ellen Grant; Beow Y Yeap; William E Butler; Nancy J Tarbell Journal: Int J Radiat Oncol Biol Phys Date: 2009-03-01 Impact factor: 7.038
Authors: Lilie L Lin; Issam El Naqa; Jeffrey R Leonard; Tae Sung Park; Abby S Hollander; Jeff M Michalski; David B Mansur Journal: J Neurosurg Pediatr Date: 2008-02 Impact factor: 2.375
Authors: H L Weiner; J H Wisoff; M E Rosenberg; M J Kupersmith; H Cohen; D Zagzag; T Shiminski-Maher; E S Flamm; F J Epstein; D C Miller Journal: Neurosurgery Date: 1994-12 Impact factor: 4.654
Authors: Jinsoo Uh; Thomas E Merchant; Yimei Li; Xingyu Li; Noah D Sabin; Daniel J Indelicato; Robert J Ogg; Frederick A Boop; John A Jane; Chiaho Hua Journal: Int J Radiat Oncol Biol Phys Date: 2015-05-16 Impact factor: 7.038
Authors: Stephen R Grant; David R Grosshans; Stephen D Bilton; John A Garcia; Mayank Amin; Mark S Chambers; Susan L McGovern; Mary F McAleer; William H Morrison; Winston W Huh; Michael E Kupferman; Anita Mahajan Journal: Radiother Oncol Date: 2015-07-28 Impact factor: 6.280
Authors: Michael S Rutenberg; Ronny L Rotondo; Dinesh Rao; Adam L Holtzman; Daniel J Indelicato; Soon Huh; Christopher G Morris; William M Mendenhall Journal: J Neurooncol Date: 2020-02-21 Impact factor: 4.130